San Francisco, CA, United States of America

Brett Permack

USPTO Granted Patents = 4 

Average Co-Inventor Count = 6.0

ph-index = 2

Forward Citations = 29(Granted Patents)


Company Filing History:


Years Active: 2007-2014

Loading Chart...
4 patents (USPTO):Explore Patents

Certainly! Here is the article about inventor Brett Permack:

Title: Spotlight on Inventor Brett Permack: Pioneering Chemokine Receptor Antagonist Innovations in San Francisco

Introduction:

Brett Permack, a highly accomplished inventor based in San Francisco, CA, is making waves in the field of pharmaceutical innovation with his groundbreaking work in developing potent antagonists of chemokine receptors.

Latest Patents:

Permack's latest patents include Bis-aryl sulfonamides - compounds that exhibit strong antagonistic properties towards chemokine receptors. These aryl sulfonamide derivatives have shown promising potential in pharmaceutical compositions, treatment methods for chemokine receptor-related diseases, and as valuable tools in assays for discovering chemokine antagonists.

Career Highlights:

Currently affiliated with Chemocentryx, Inc., a renowned biopharmaceutical company at the forefront of developing novel therapies, Permack's contributions have significantly advanced the understanding and treatment of chemokine receptor-mediated conditions.

Collaborations:

In his innovative journey, Permack has collaborated closely with esteemed colleagues such as Solomon Ungashe and Zheng Wei, fostering a dynamic environment that stimulates creativity and fosters scientific breakthroughs.

Conclusion:

Inventor Brett Permack's impressive portfolio of patents and his dedication to pushing the boundaries of pharmaceutical innovation underscore his status as a pioneering force in the field. His remarkable work stands as a testament to the transformative potential of advancements in chemokine receptor research and its profound impact on the healthcare landscape.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…